Onychopathy Following Durvalumab Treatment for Extensive-Stage Small-Cell Lung Cancer: A Case Report

Patients treated with immune checkpoint inhibitors (ICIS) are prone to immune related adverse events (irAEs), making it important to pay attention to these adverse events. Herein, we report a case of onychopathy after treatment of extensive small cell lung cancer (ES-SCLC) with durvalumab; this is t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Cuifen, Wang, Ke, Zhang, Hong, Liu, Jingjing, Zheng, Chuangjie, Tao, Jiahao, Lin, Lizhu, Zhai, Linzhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492564/
https://www.ncbi.nlm.nih.gov/pubmed/37694194
http://dx.doi.org/10.2147/CCID.S415119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492564/
https://www.ncbi.nlm.nih.gov/pubmed/37694194
http://dx.doi.org/10.2147/CCID.S415119

Ejemplares similares